Peter C. B. Bynoe
Peter C. B. Bynoe's purchase track record
Peter C. B. Bynoe has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/16/2025 | TKO | $150K | +5.6% | +0.8% | +1.7% |
| 6/5/2025 | TKO | $166K | +12.8% | +19.6% | +15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ARDT Schedules Q3 2026 Results Call and Webcast. Ardent Health announced the date for its third quarter 2026 earnings conference call and webcast. The call will provide management’s discussion of the latest financial results and operational updates. Investors often use such events to assess performance trends, especially as the stock currently shows strong momentum on the chart.
Transaction History
| TKO | ▲ Buy | Option Exercise | 1,237 | $0 | 6/10/2026 | View on chart |
| ARDT | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 | View on chart |
| TKO | ▲ Buy | Open Market | 740 | $150K | 9/16/2025 | View on chart |
| TKO | ▲ Buy | Option Exercise | 1,700 | $0 | 6/12/2025 | View on chart |
| TKO | ▲ Buy | Open Market | 980 | $166K | 6/5/2025 | View on chart |
| ARDT | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 | View on chart |
| ARDT | ▲ Buy | Grant | 10,793 | $0 | 12/12/2024 | View on chart |
| ARDT | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 | View on chart |
| TKO | ▲ Buy | Option Exercise | 1,767 | $0 | 6/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TKO Group Holds Positive Analyst View as Price Target Adjusted to $224
TKO Group reported its Q2 2026 earnings in a conference call, giving details on recent performance and outlook. After the call, Susquehanna analysts kept a positive stance on the stock but lowered their price target to $224. The change reflects the analyst’s view of the company’s valuation based on the latest results.
TKO Group Holds Positive Analyst View as Price Target Adjusted to $224. TKO Group reported its Q2 2026 earnings in a conference call, giving details on recent performance and outlook. After the call, Susquehanna analysts kept a positive stance on the stock but lowered their price target to $224. The change reflects the analyst’s view of the company’s valuation based on the latest results.